Cagrilintide
Also known as: NN9838
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.
Pricing for Cagrilintide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Cagrilintide
69 third-party tests across 18 vendors. Each card links to the full report.
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide
by Nox Amino· batch NA-CG0526-01
For
Cagrilintide
by NG Peptide· batch CG10-12
For
Cagrilintide
by Crush Research· batch CRCAG-5-2604-1
For
Cagrilintide
by Qihang Peptide· batch 4
For
Cagrilintide
by Amino Club· batch CAG0001
For
Cagrilintide
by Ion Peptide· batch CAC10-03192026
For
Cagrilintide
by Mile High Compounds· batch CAG-010-MH-02
For
Cagrilintide
by Glacier Aminos· batch CAG10GA-03
For
Cagrilintide
by Real Peptides
For
Cagrilintide
by Simple Peptide· batch GRCG1025-0226-I
For
Cagrilintide
by Glacier Aminos· batch CAG10GA-02
For
Cagrilintide
by Ion Peptide
For
Cagrilintide
by Ion Peptide
For
Cagrilintide
by Peptide Supply Co.· batch PSCCGL10001
For
Cagrilintide
by BioLongevity Labs· batch 6-3-46031
For
Cagrilintide Amylin Analog
by BioLongevity Labs· batch 6-3-46031
For
Cagrilintide
by Simple Peptide· batch CAGLOU142026-J
For
Cagrilintide
by Glacier Aminos· batch CAG5GA01
For
Cagrilintide
by Ion Peptide· batch CG10-121925
For
Cagrilintide
by Ion Peptide· batch CGL10-12125
For
Cagrilintide
by Ion Peptide· batch CAG5-1125
For
Cagrilintide
by Riptide Wellness· batch RWCAG-10-1001
For
Cagrilintide
by Skye Peptides· batch CAG25-10-002
27 citations indexed for Cagrilintide
review · 2026
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis
Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
rct · 2026
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
Background The combination of cagrilintide and semaglutide has been shown in global studies to induce reductions in bodyweight. We assessed the efficacy and safety of a fixed-dose combination of cagrilintide 2·4 mg and semaglutide 2·4 mg versus semaglutide 2·4 mg for weight management in an east Asian population.
meta-analysis · 2026
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression
Background Obesity is a complex chronic disease requiring effective long-term management. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
Study · 2026
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research
Peptide hormone-based weight-loss therapeutics have gained increasing attention, driven amongst other reasons, by the clinical and commercial success of semaglutide.
Study · 2026
Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro
Background Incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1Ras), dual GLP-1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits. However, their impact on skeletal muscle mitochondrial function, particularly under metabolic stress, remains unclear.